Alzheimer’s Disease Month at Randox Biosciences
Alzheimer’s Disease Month at Randox Biosciences
15 September 2020
Alzheimer’s Risk Array from Randox Biosciences
September 2020 marks the 9th World Alzheimer’s Month
World Alzheimer’s Month is the international campaign every September to raise awareness and challenge the stigma that surrounds dementia. Alzheimer’s Disease is a progressive neurodegenerative disease associated with cognitive decline and is the most common form of dementia. It is defined as an irreversible, progressive brain disorder in which parts of the brain are damaged over time.
According to Alzheimer’s Disease International dementia affects people differently – no two people will experience symptoms in exactly the same way. A person’s personality, general health and social situation are all important factors in determining the impact of dementia on an individual. The most common signs are memory loss, the loss of practical abilities, problems with language, changes in mood and behaviour, and withdrawal from work or social activities.1
Who is affected?
- There are currently around 850,000 people with dementia in the UK. This is projected to rise to 1.6 million by 2040.2
- 209,600 will develop dementia this year, that’s one every three minutes.2
- 1 in 6 people over the age of 80 have dementia.2
- 70% of people in care homes have dementia or severe memory problems.2
- There are over 42,000 people under 65 with dementia in the UK.2
The Randox Alzheimer’s Risk Array is a rapid and highly sensitive blood test facilitating direct Apo E genotyping without the need for molecular testing. Apo E is present in three common isoforms; Apo E2, Apo E3 and Apo E4. Alzheimer’s Disease risk is increased in individuals with the Apo E4 allele.
Apolipoprotein E (ApoE) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. ApoE polymorphic alleles are the main genetic determinants of Alzheimer Disease risk. Presence of ApoE4 allele is associated with increased risk for cerebral amyloid angiopathy and age-related cognitive decline during normal ageing.3
Apo E4 is one of three common isoforms of Apo E and is recognised as a major genetic risk factor the development of Alzheimer’s disease. Apo E4 triggers inflammatory cascades that cause neurovascular dysfunction, including blood-brain barrier breakdown, leakage of blood-derived toxic proteins into the brain and reduction in the length of small vessels.
Utilising revolutionary patented Biochip Technology, the Randox Alzheimer’s Risk Array provides a unique solution for the measurement of both total apoE and the apo E4 isoform levels from a single patient sample, facilitating the fast and accurate classification of Alzheimer’s disease risk in comparison to brain scanning (CT and MRI).
Key Benefits of Alzheimer’s Risk Array
- 2-plex testing from a single sample
- Assist in research and development of potential treatment
- Early risk detection of disease
- Small sample volume
- Fast throughput
Biochip Technology
Biochip Technology is an immunoassay testing platform and is the core of Randox Biosciences. The intelligent chemically activated 9x9mm ceramic biochip acts as a solid phase reaction vessel. Benefits of Biochip Technology include:
- The biochips are pre-fabricated with discrete test regions (DTR’s)
- Highly accurate testing
- Better diagnosis
- Reduced sample volume
- Wide test menu
- Multiple sample types can be used on a Biochip
- Cost consolidation
Evidence Investigator
The Evidence Investigator offers a high throughput even as a compact, semi-automated analyser promoting lab efficiency and cost saving solutions. Utilising Randox’s patented Biochip Technology, this platform facilitates multiplex testing in a rapid, accurate and easy-to-use format providing a comprehensive patient profile from one single sample. This analyser is suitable for medium throughput laboratories and is extremely robust with only one moving part.
For further information on our early risk detection testing for Alzheimer’s Disease, please email info@randoxbiosciences.com
References
- https://www.alz.co.uk/info/early-symptoms
- https://www.alzheimers.org.uk/about-us/news-and-media/facts-media
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898682/
RESEARCH
BIOPHARMA
CLINICAL LAB
BIOREAGENTS
Cerebral Array II from Randox Biosciences
13 August 2020
Cerebral Array II from Randox Biosciences
Randox Biosciences’ Cerebral Array II has been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer’s disease and multiple sclerosis. The array harnesses multiplex testing measuring up to five biomarkers simultaneously using a single patient sample with a turnaround time of 2.5 hours. It is suitable for human serum, plasma and cerebrospinal fluid (CSF) samples. Our Cerebral Array II offers excellent sensitivity, precision and recovery as well as analytical performance.
Cerebral Array II
- C-Reactive Protein (CRP)
- D-Dimer
- Neuron Specific Enolase (NSE)
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Soluble Tumour Necrosis Factor Receptor I (sTNFRI)
Key Benefits of Cerebral Array II
- Multiplex testing from a single sample
- Suitable for human serum, plasma and cerebrospinal fluid (CSF) samples
- Small sample volume
- Excellent analytical performance
- Fast throughput
- Applicable to fully automated and semi-automated Evidence platforms
Your central nervous system is your body’s control centre which includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your senses to the muscles throughout your body. When this is damaged, triggered by an illness or injury it can disturb many functions including memory, sensation and even a person’s personality.1 Up to 1 billion people (1 in 6 of the world’s population) suffer from neurological disorders from Alzheimer and Parkinson Disease, strokes, multiple sclerosis and epilepsy.2
World Health Organisation (WHO) categorizes neurological disorders in two groups which is shown in the table below3. Group one is classified as neurological disorders in neuropsychiatry which are non-communicable diseases (NCD). NCD is a disease that is not transmissible directly from one person to another. Group two are disorders/injuries with neurological sequelae meaning a pathological condition resulting from a prior disease, injury, or attack.
| GROUP ONE | GROUP TWO |
| Epilepsy | Cerebrovascular disease |
| Alzheimer and Other Dementias | Neuroinfectious |
| Parkinson’s Disease | Nutritional deficiencies and neuropathies |
| Multiple Sclerosis | Neurological injuries |
| Migraine |
Randox Biosciences can assist in cerebrovascular research by providing innovative diagnostic technology and tests that will continue to revolutionise the healthcare industry and assist in academic research. This technology includes our Evidence Investigator and our Cerebral Array II which can be used to assist in the discovery and research of Cerebral diseases.
Biochip Technology
Biochip Technology is an immunoassay testing platform and is the core of Randox Biosciences. The intelligent chemically activated 9x9mm ceramic biochip acts as a solid phase reaction vessel. Benefits of Biochip Technology include:
- The biochips are pre-fabricated with discrete test regions (DTR’s)
- Highly accurate testing
- Better diagnosis
- Reduced sample volume
- Wide test menu
- Multiple sample types can be used on a Biochip
- Cost consolidation
Evidence Investigator
The Evidence Investigator offers a high throughput even as a compact, semi-automated analyser promoting lab efficiency and cost saving solutions. Utilising Randox’s patented Biochip Technology, this platform facilitates multiplex testing in a rapid, accurate and easy-to-use format providing a comprehensive patient profile from one single sample. This analyser is suitable for medium throughput laboratories and is extremely robust with only one moving part.
For further information on our Cerebral Array please visit the Randox Biosciences website.
For any other enquiries please email info@randoxbiosciences.com
References:
RESEARCH
BIOPHARMA
CLINICAL LAB
BIOREAGENTS
Randox Cerebral Arrays on the Evidence Series Immunoanalysers
The Evidence is the world’s first protein Biochip Array Technology Analyser (BAT). The awarding winning Biochip Array Technology is a multi-analyte testing platform allowing the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
The Evidence is a fully automated immunoanalyser which is renowned for higher standards of quality, efficiency and reliability. It is tailored and more suitable in a wide range of settings including hospital laboratories, clinical laboratories, private and public research applications, veterinary laboratories, forensic and clinical toxicology and pharmaceutical applications.
There are many key features for The Evidence, including the ability to carry out multiplex testing which will allow multiple tests to be carried out from a single patient sample as a result. It reduces the amount of labour spent on the individual tests and therefore saves money and time. The analyser is more suitable for larger laboratories with a throughput of >1500 tests per hour with a fully automated system maximising the walk away time – allowing staff to devote their time to other important tasks.
The multi-analyte barcoded controls and calibrators ensure security, accuracy and reliable laboratory testing. They also allow for full traceability making the overall experience easier. It offers a wide-ranging and diverse test menu which offer more tests than other sole suppliers and this will benefit many research areas including immunology, metabolic, cardiovascular and oncology.
Neurological conditions can affect young and old people and result from damage to the brain, spine or nerves which is triggered by an illness or an injury1. Up to 1 billion people (one in six of the world’s population suffer from neurological disorders from Alzheimer and Parkinson disease, strokes, multiple sclerosis and epilepsy 2. In England the number of deaths from neurological disorders have rose by 39% over the past 13 years3.
Randox offers two Cerebral Arrays which have been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer’s disease and multiple sclerosis. The Arrays can measure up to five biomarkers simultaneously. They are suitable for human serum, plasma and cerebrospinal fluid (CSF) samples. Additionally, it offers excellent sensitivity, precision and recovery as well as analytical performance.
For more information on our Evidence Series or Cerebral range of Assays, contact us at EvidenceSeries@randox.com
- http://www.neural.org.uk/living-with-a-neurological-condition/what-is-a-neurological-condition
- https://news.un.org/en/story/2007/02/210312-nearly-1-6-worlds-population-suffer-neurological-disorders-un-report
- https://www.bmj.com/content/360/bmj.k1278
